zantac 150mg dispersible tablets
aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, dispersible - excipient ingredients: magnesium stearate; croscarmellose sodium; microcrystalline cellulose; hyprolose; titanium dioxide; saccharin sodium; hypromellose; flavour - 1. short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. treatment of scleroderma oesphagitis. the intravenous injection is indicated where oral treatment is inappropriate
zantac 150 mg/10ml syrup
ltt pharma limited - ranitidine hydrochloride - syrup - 150 mg/10ml - h2-receptor antagonists
zantac 300 mg film coated tablet
ltt pharma limited - ranitidine hydrochloride - film coated tablet - 300 mg - h2-receptor antagonists
zantac 150 mg film coated tablet
ltt pharma limited - ranitidine hydrochloride - film coated tablet - 150 mg - h2-receptor antagonists
zantac solution for injection or infusion 25mg/ml
glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - ranitidine - solution for infusion or injection - ranitidine 25 mg/ml - drugs for acid related disorders
zantac 25 mg/ml solution for injection/infusion
glaxosmithkline (ireland) limited - ranitidine - solution for injection/infusion - 25 milligram(s)/millilitre - h2-receptor antagonists; ranitidine
zantac 150 mg effervescent tablets
glaxosmithkline (ireland) limited - ranitidine hydrochloride - effervescent tablet - 150 milligram(s) - h2-receptor antagonists; ranitidine
zantac 150 mg/10 ml syrup
glaxosmithkline (ireland) limited - ranitidine hydrochloride - syrup - 150 milligram/ 10 millilitre - h2-receptor antagonists; ranitidine
zantac 50mg/2ml solution for injection ampoules
glaxosmithkline uk ltd - ranitidine hydrochloride - solution for injection - 25mg/1ml
zantac syrup 150mg/10ml
glaxosmithkline pharmaceutical sdn. bhd. - ranitidine hydrochloride -